Variable . | Nonsevere hypoglycemia . | No nonsevere hypoglycemia . |
---|---|---|
Total n | 3,256 | 8,239 |
Age, years | 62.8 (7.4) | 63.5 (7.8)A |
Female | 1,013 (31.1) | 2,762 (33.5)B |
Education | ||
<8 years | 1,066 (32.7) | 2,637 (32.0) |
9–12 years | 914 (28.0) | 2,279 (27.7) |
>12 years | 1,276 (39.2) | 3,321 (40.3) |
Ethnicity | ||
White | 1,843 (56.6) | 5,193 (63.0)A |
Black | 86 (2.6) | 218 (2.6) |
South Asian | 112 (3.4) | 316 (3.8) |
Other Asian | 183 (5.6) | 550 (6.7)B |
Latin | 966 (29.7) | 1,743 (21.2)A |
Other | 66 (2.0) | 218 (2.6) |
Depression3 | 547 (16.8) | 1,071 (13)A |
Mean BMI | 29.6 (5.1) | 30.0 (5.3)A |
Previous CVD1 | 1,947 (59.8) | 4,880 (59.2) |
Hypertension | 2,562 (78.7) | 6,511 (79.0) |
Hyperlipidemia | 2,198 (67.5) | 5,488 (66.6) |
Current smoker | 445 (13.7) | 1,018 (12.4) |
Alcohol2 | 810 (24.9) | 1,928 (23.4) |
Previous DM | 3,049 (93.6) | 7,082 (86.0)A |
DM duration, years | 6.3 (6.4) | 4.9 (5.6)A |
Mean A1C, % | 6.7 (1.0) | 6.4 (0.9)A |
Mean FPG, mmol/L | 7.6 (2.1) | 7.2 (1.9)B |
Glargine allocation | 2,429 (74.6) | 3,328 (40.4)A |
Standard allocation | 827 (25.4) | 4,911 (59.6)A |
n-3 allocation | 1,621 (49.8) | 4,164 (50.5) |
Placebo allocation | 1,635 (50.2) | 4,074 (49.4) |
Metformin | 879 (27.0) | 2,253 (27.3) |
Sulfonylurea | 1,310 (40.2) | 1,986 (24.1)A |
Other glucose-lowering drugs | 101 (3.1) | 234 (2.8) |
Mean MMSE score | 28.4 (1.8) | 28.5 (1.7)B |
Variable . | Nonsevere hypoglycemia . | No nonsevere hypoglycemia . |
---|---|---|
Total n | 3,256 | 8,239 |
Age, years | 62.8 (7.4) | 63.5 (7.8)A |
Female | 1,013 (31.1) | 2,762 (33.5)B |
Education | ||
<8 years | 1,066 (32.7) | 2,637 (32.0) |
9–12 years | 914 (28.0) | 2,279 (27.7) |
>12 years | 1,276 (39.2) | 3,321 (40.3) |
Ethnicity | ||
White | 1,843 (56.6) | 5,193 (63.0)A |
Black | 86 (2.6) | 218 (2.6) |
South Asian | 112 (3.4) | 316 (3.8) |
Other Asian | 183 (5.6) | 550 (6.7)B |
Latin | 966 (29.7) | 1,743 (21.2)A |
Other | 66 (2.0) | 218 (2.6) |
Depression3 | 547 (16.8) | 1,071 (13)A |
Mean BMI | 29.6 (5.1) | 30.0 (5.3)A |
Previous CVD1 | 1,947 (59.8) | 4,880 (59.2) |
Hypertension | 2,562 (78.7) | 6,511 (79.0) |
Hyperlipidemia | 2,198 (67.5) | 5,488 (66.6) |
Current smoker | 445 (13.7) | 1,018 (12.4) |
Alcohol2 | 810 (24.9) | 1,928 (23.4) |
Previous DM | 3,049 (93.6) | 7,082 (86.0)A |
DM duration, years | 6.3 (6.4) | 4.9 (5.6)A |
Mean A1C, % | 6.7 (1.0) | 6.4 (0.9)A |
Mean FPG, mmol/L | 7.6 (2.1) | 7.2 (1.9)B |
Glargine allocation | 2,429 (74.6) | 3,328 (40.4)A |
Standard allocation | 827 (25.4) | 4,911 (59.6)A |
n-3 allocation | 1,621 (49.8) | 4,164 (50.5) |
Placebo allocation | 1,635 (50.2) | 4,074 (49.4) |
Metformin | 879 (27.0) | 2,253 (27.3) |
Sulfonylurea | 1,310 (40.2) | 1,986 (24.1)A |
Other glucose-lowering drugs | 101 (3.1) | 234 (2.8) |
Mean MMSE score | 28.4 (1.8) | 28.5 (1.7)B |
For categorical outcomes, values are n (%). For continuous variables, the mean (SD) is given. DM, diabetes mellitus.
1Defined as previous revascularization, myocardial infarction, or stroke. 2More than two drinks consumed in a week. 3Defined as an affirmative answer regarding the question of feeling “sad, low in spirits, or depressed for 2 or more weeks” and during that time also having “thought a lot about death or required treatment for depression.”
P < 0.001.
P = < 0.05.